TEL AVIV, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on the “Investors” page on its website. Q2 2025 Aide Memoire Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva’s prior results, management’s previous commentary about Teva’s business outlook and data from select independent sources. About Teva Teva Pharmaceutical Indus ...

Amneal Pharmaceuticals (AMRX) FY Conference June 10, 2025 10:40 AM ET Speaker0 Okay. Great. Well, thank you everyone for joining us today. My name is Matt Delatorre, and I'm the generics pharma analyst here at GS. And we're we're very pleased to have Amneal Pharmaceuticals with us for this session with Sharag Patel, cofounder and co CEO, and Tassos Konidaris, the chief financial officer. Great. So maybe maybe just to get started, you know, how about just level set us on where Amneal is headed from kind of a ...

Core Insights - Emerging markets are crucial for Boston Scientific Corporation's (BSX) growth strategy, with a 9.8% year-over-year operational sales growth in Q1 2025 despite geopolitical challenges [1][8] - The medical device industry is experiencing strong growth opportunities in emerging markets, driven by trends such as preventive healthcare and digital health adoption [2] - Boston Scientific's sustained investment and localized strategies position it well to capture future growth in these high-potential regions [3] Emerging Market Performance - BSX's emerging market operations delivered robust sales growth of approximately 9.8% year over year in Q1 2025, supported by favorable economic trends and expanding healthcare infrastructure [1][8] - India’s medical device market is projected to grow from $15.35 billion in 2023 to $20.51 billion by 2029, reflecting a CAGR of 5.35% [2] - China and Brazil are highlighted as key markets due to their large populations and expanding economies, with Southeast Asian countries also gaining importance [2] Competitive Landscape - Competition in emerging markets is intense, with Abbott Laboratories and Medtronic actively expanding their global reach [4] - Abbott's Established Pharmaceuticals Division, focused on emerging markets, reported high single-digit organic growth in Q1 2025, driven by strong demand across Asia, Latin America, and the Middle East [5] - Medtronic generated nearly 49% of its revenues from international markets, with mid-single-digit growth in its emerging market business, particularly in India and Southeast Asia [6] Financial Performance - BSX shares have increased by 35.8% over the past year, outperforming the industry growth of 9.6% and the S&P 500's growth of 12.2% [7][8] - The company trades at a forward price-to-earnings ratio of 33.69, which is above the industry average of 21.73 [9] - The Zacks Consensus Estimate for BSX's earnings has been rising, indicating positive sentiment among analysts [10]

Core Viewpoint - Teva Pharmaceutical Industries Ltd. has announced the pricing and early acceptance results of its tender offers to purchase outstanding notes issued by its finance subsidiaries, with specific terms and conditions outlined in the Offer to Purchase dated May 19, 2025 [1][10]. Summary by Relevant Sections Tender Offer Details - The early acceptance results indicate the total consideration for each series of notes, with specific amounts tendered and accepted [2][8]. - The total maximum amount and pool tender caps for the offers are set at $1,550 million for Pool 1, $350 million for Pool 2, and $400 million for Pool 3 [2][3]. Acceptance Priority Levels - Notes tendered with Acceptance Priority Level 4 will be accepted in full without proration, while those with Levels 1, 2, and 5 will be accepted subject to proration factors of approximately 60.75%, 39.46%, and 36.66%, respectively [8][9]. Financial Conditions - The settlement of Teva's $2.3 billion senior notes offering on May 28, 2025, satisfied the financing condition for the tender offers [12]. - The purchase price for the Dollar Notes and Euro Notes will be paid in their respective currencies [12]. Timeline and Conditions - The initial settlement date is expected to occur on June 5, 2025, with the offers set to expire at 5:00 p.m. Eastern Time on June 17, 2025, unless extended or terminated earlier [11][9]. - Teva reserves the right to amend or waive conditions related to the offers [10]. Company Overview - Teva Pharmaceutical Industries Ltd. operates as a global biopharmaceutical leader, focusing on innovation and the production of generics and biologics, with a commitment to advancing health for over 120 years [16].

WARREN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that it will provide several updates to stockholders in advance of the Company’s upcoming Annual Meeting of Stockholders scheduled for June 23, 2025. These updates will provide content regarding the Company’s innovative business model and strategic growth initiatives, which management believes position the Company strongly for future value realization. Ahead of the annual meeting ...

Core Insights - PetMed Express, Inc. has announced a strategic partnership with Dutch to enhance its pet healthcare ecosystem by providing affordable and accessible veterinary care options [1][2] - The collaboration aims to address the nationwide veterinarian shortage, which has left over 129 million Americans without easy access to pet care [2][3] Company Overview - PetMed Express, Inc. is a leader in the consumer pet healthcare sector, offering a wide range of pharmaceuticals, generics, compounded medications, and OTC supplements through its online platforms [4] - The company operates under the brands PetMeds and PetCareRx, delivering services across all fifty states [4] Partnership Details - The partnership allows pet parents to sign up for a monthly Dutch membership, providing virtual access to veterinarians for 24/7 appointments in 34 states [2] - Dutch has completed nearly 700,000 visits and treats over 150 conditions, including flea and tick medication and treatments for allergies and joint pain [2] Industry Context - The 2025 State of Veterinary Care Report indicates that approximately 38% of the U.S. population lives in areas lacking adequate veterinary care, highlighting the need for telehealth solutions [3] - Dutch, launched in July 2021, connects licensed veterinarians with pet owners and has expanded its services to include prescription medications, addressing the critical vet shortage in the U.S. [5]